SciBase Interim report

SciBase Interim report

PR Newswire

STOCKHOLM, Nov. 10, 2022

STOCKHOLM, Nov. 10, 2022 /PRNewswire/ -- 

January 1 - September 30, 2022

The third quarter in figures

January - September in figures

Important events during the quarter

Important events after the end of the  period




July 1 - Sep 30

Jan 1 - Sep 30

Oct 1, 2021 - 
Sep 30, 2022

Jan 1 - Dec 31

THE GROUP

2022

2021

2022

2021

Rolling-12

2021

Net sales, SEK ths

4 941

2 982

12 927

7 802

16 852

11 727

Gross margin, %

58,4 %

63,3 %

63,3 %

57,8 %

60,9 %

56,1 %

Equity/Asset ratio, %

72,5 %

86,8 %

72,5 %

86,8 %

81,8 %

82,8 %

Net indebtness, multiple

0,38

0,15

0,38

0,15

0,22

0,21

Cash equivalents, SEK ths

34 014

78 270

34 014

78 270

34 014

65 607

Cashflow from operating activities, SEK ths

-9 718

-9 156

-29 873

-27 792

-41 583

-39 501

Earnings per share (before and after dilution), SEK

-0,13

-0,13

-0,40

-0,46

-0,61

-0,67

Shareholder's equity per share, SEK

0,57

1,24

0,57

1,40

0,90

1,13

Average number of shares, 000'

68 475

68 475

68 475

60 827

68 465

62 739

Number of shares at closing of period, 000'

68 475

68 475

68 475

68 475

68 475

68 475

Share price at end of period, SEK

3,70

4,88

3,70

4,88

3,70

5,52

Number of sold electrodes, pieces

10 592

8 304

30 172

21 768

38 196

29 792

Average number of employees

20

17

19

17

19

17

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 10, 2022.

This report has been comprehensively reviewed by the Company's auditors.

Contact person:

Michael Colérus, CFO, +46 70 341 34 72

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor (CA):

Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se

About SciBase and Nevisense

SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases 

The following files are available for download:

https://mb.cision.com/Main/12371/3664498/1660674.pdf

Interim report Q3 2022 final clean

Cision View original content:https://www.prnewswire.co.uk/news-releases/scibase-interim-report-301674060.html

Voltar noticias em Inglês